99 Results for "

VEGF receptor

" in MedChemExpress (MCE) Product Catalog:
Products (99)

99 Results for "VEGF receptor" in MCE Product Catalog:

16
16 Publications Verification
Cat. No.: HY-N0637
CAS No.: 552-58-9
Synonyms: Huazhongilexone
Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC50=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-10799
CAS No.: 1210945-69-9
Purity:  98.03%
Target:  

Complement System

Research Areas:  

Cancer

EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-17369B
CAS No.: 144494-65-5
Synonyms: L700462; MK383
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-17369
CAS No.: 150915-40-5
Synonyms: L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108628
CAS No.: 251356-45-3
Purity:  99.36
Target:  

PDGFR

Research Areas:  

Cancer

SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P70147
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane receptor; Neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; Neuropilin; Neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 receptor
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-113649
CAS No.: 1007377-55-0
Purity:  99.95%
Research Areas:  

Cancer

AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P81643
Synonyms: KDR; FLK1; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, ICC/IF, ELISA

Reactivity:  

Human, Mouse

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121356
CAS No.: 90729-42-3
Purity:  99.23%
Carebastine is an Ebastine (HY-B0674) metabolite and H1-receptor antagonist. Carebastine inhibits VEGFR-2 and Akt phosphorylation. Carebastine exerts an anti-inflammatory effect by inhibiting MIF as well as TNF-α and IL-6 production. Carebastine shows anti-angiogenic activity
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-17617
CAS No.: 209219-38-5
Synonyms: Z-360
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18963
CAS No.: 125697-92-9
Synonyms: RG-14355
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108551
CAS No.: 179324-22-2
Purity:  ≥95.0%
Synonyms: Z-Leu-Leu-LeuB(OH)2; ZL3B
MG-262 (Z-Leu-Leu-LeuB(OH)2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS). MG-262 can be used for anti-cancer study .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119442
CAS No.: 143816-42-6
Target:  

Leukotriene Receptor

Research Areas:  

Cardiovascular Disease

Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC50s of 1.2 and 52 μM for CysLT1R and CysLT2R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents .
loading...
    loading...
Cat. No.: HY-P99330
CAS No.: 1448221-05-3
Synonyms: Anti-Human VEGFA Recombinant Antibody; RO5520985

Target:  

VEGFR Tie

Research Areas:  

Cancer

Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
loading...
    loading...
Cat. No.: HY-B0164
CAS No.: 108612-45-9
Target:  

Histamine Receptor

Research Areas:  

Inflammation/Immunology

Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .
loading...
    loading...
Cat. No.: HY-N0637A
CAS No.: 4049-38-1
Synonyms: (±)-Huazhongilexone; Dihydroluteolin
(±)-Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC50=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. (±)-Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. (±)-Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. (±)-Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. (±)-Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .
loading...
    loading...
Cat. No.: HY-P5558
CAS No.: 917760-16-8
Target:  

VEGFR

Research Areas:  

Neurological Disease

KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair .
loading...
    loading...
Cat. No.: HY-103325
CAS No.: 282089-49-0
Purity:  98.72%
JTE-907 is a selective and orally active cannabinoid CB2 receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis .
loading...
    loading...
Cat. No.: HY-P3369
CAS No.: 2417491-82-6
Synonyms: AXT-107
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGF receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .
loading...
    loading...
Cat. No.: HY-P99830
CAS No.: 1227158-72-6
Synonyms: KH902
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
loading...
    loading...